全文获取类型
收费全文 | 62篇 |
免费 | 9篇 |
国内免费 | 2篇 |
专业分类
基础医学 | 7篇 |
临床医学 | 1篇 |
内科学 | 50篇 |
外科学 | 9篇 |
眼科学 | 1篇 |
药学 | 1篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 3篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 4篇 |
2019年 | 8篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 7篇 |
2013年 | 8篇 |
2012年 | 5篇 |
2011年 | 1篇 |
2010年 | 2篇 |
2009年 | 1篇 |
2008年 | 1篇 |
2007年 | 2篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 2篇 |
2002年 | 1篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1987年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有73条查询结果,搜索用时 46 毫秒
1.
Kinugasa Eriko Igawa Ken Shimada Hisaki Kondo Morihiro Funakoshi Satoshi Imada Naoki Itami Noritomo Fukazawa Naoki Takubo Ryoko Kawata Yuichi Murota Hiroyuki 《Clinical and experimental nephrology》2021,25(8):875-884
Clinical and Experimental Nephrology - The pathophysiology of uremic pruritus (UP), which is characterized by systemic and intractable itching, remains unclear. As interleukin (IL)-31 may be... 相似文献
2.
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Masanori Atsukawa Keizo Kato Hiroshi Abe Noritomo Shimada Toru Asano Tadashi Ikegami Mai Koeda Tomomi Okubo Taeang Arai Ai Nakagawa‐Iwashita Yuji Yoshida Korenobu Hayama Norio Itokawa Chisa Kondo Yoshimichi Chuganji Yasushi Matsuzaki Katsuhiko Iwakiri 《Journal of gastroenterology and hepatology》2018,33(6):1256-1263
3.
Noritomo Shimada Hidenori Toyoda Akihito Tsubota Tatsuya Ide Koichi Takaguchi Keizo Kato Masaki Kondoh Kazuhiro Matsuyama Takashi Kumada Michio Sata 《Journal of gastroenterology》2014,49(11):1485-1494
Background
Genetic polymorphisms near Interleukin 28B (IL28B) (rs8099917) and a rapid virological response (RVR) have been reported as predictors for a sustained virological response (SVR) to telaprevir (TVR)-based triple combination therapy. However, the association between SVR and viral kinetics earlier than week 4 after initiation of therapy remains unclear. Thus, we evaluated the SVR prediction ability of baseline factors and reduced hepatitis C virus (HCV) RNA levels at week 1 after the initiation of TVR-based therapy in Japanese genotype-1b chronic hepatitis C (CHC) patients.Methods
A total of 156 Japanese CHC patients received a 24-week regimen of TVR-based therapy. Baseline factors and reduction in HCV RNA levels at weeks 1 and 4 after the initiation of therapy were analyzed for SVR prediction.Results
Multiple logistic regression analysis for SVR in TVR-based therapy identified the IL28B TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1, RVR, and treatment-naïve/relapse. Whereas the SVR rate was higher than 90 % regardless of the reduction in HCV RNA levels at week 1 in patients with the TT genotype, a reduction of ≥4.7 log10IU/mL in HCV RNA levels at week 1 was the strongest predictor of SVR in patients with the non-TT genotype, as determined by multiple logistic regression analysis (P = 0.0043).Conclusions
The IL28B TT genotype is the most important baseline factor for predicting SVR, and a ≥4.7 log10IU/mL reduction in HCV RNA at week 1 is a useful very early on-treatment predictor of SVR, especially in the non-TT genotype. 相似文献4.
Masanori Atsukawa Akihito Tsubota Hidenori Toyoda Koichi Takaguchi Makoto Nakamuta Tsunamasa Watanabe Kojiro Michitaka Tadashi Ikegami Akito Nozaki Haruki Uojima Shinya Fukunishi Takuya Genda Hiroshi Abe Naoki Hotta Kunihiko Tsuji Chikara Ogawa Yoshihiko Tachi Toshihide Shima Noritomo Shimada Chisa Kondo Takehiro Akahane Yoshio Aizawa Yasuhito Tanaka Takashi Kumada Katsuhiko Iwakiri 《Alimentary pharmacology & therapeutics》2019,49(9):1230-1241
5.
6.
Atsushi Hiraoka Takashi Kumada Toshifumi Tada Masashi Hirooka Kazuya Kariyama Joji Tani Masanori Atsukawa Koichi Takaguchi Ei Itobayashi Shinya Fukunishi Kunihiko Tsuji Toru Ishikawa Kazuto Tajiri Hironori Ochi Satoshi Yasuda Hidenori Toyoda Chikara Ogawa Takashi Nishimura Takeshi Hatanaka Satoru Kakizaki Noritomo Shimada Kazuhito Kawata Atsushi Naganuma Hisashi Kosaka Tomomitsu Matono Hidekatsu Kuroda Yutaka Yata Hideko Ohama Fujimasa Tada Kazuhiro Nouso Asahiro Morishita Akemi Tsutsui Takuya Nagano Norio Itokawa Tomomi Okubo Taeang Arai Michitaka Imai Yohei Koizumi Shinichiro Nakamura Hiroko Iijima Masaki Kaibori Yoichi Hiasa Real-life Practice Experts for HCC Study Group HCC Group 《Hepatology research》2023,53(10):1031-1042
Aim
The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on bodyweight and serum albumin, and known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI in patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).Methods
A total of 525 HCC patients treated with Atez/Bev, based on their classification of unsuitable status for curative treatments and/or transarterial catheter chemoembolization, were enrolled (Child–Pugh A:B:C = 484:40:1, Barcelona Clinic Liver Cancer stage 0:A:B:C:D = 7:25:192:283:18). Prognosis was evaluated retrospectively using GNRI.Results
Atez/Bev was used in 338 of the present cohort as first-line systemic chemotherapy (64.4%). Median progression-free survival based on GNRI indicating normal, mild decline, moderate decline, and severe decline was 8.3, 6.7, 5.3, and 2.4 months, respectively, whereas median overall survival was 21.4, 17.0, 11.5. and 7.3 months, respectively (both p < 0.001). The concordance index (c-index) values of GNRI for predicting prognosis (progression-free survival/overall survival) were superior to those of Child–Pugh class and albumin-bilirubin grade (0.574/0.632 vs. 0.527/0.570 vs. 0.565/0.629). As a subanalysis, muscle volume loss was observed in 37.5% of 256 patients with computed tomography data available. Along with GNRI decline, frequency of muscle volume loss became progressively larger (normal vs. mild vs. moderate vs. severe = 17.6% vs. 29.2% vs. 41.2% vs. 57.9%, p < 0.001), and a GNRI value of 97.8 was predictive of its occurrence (AUC 0.715, 95% CI 0.649–0.781; specificity/sensitivity = 0.644/0.688).Conclusion
These findings indicate that GNRI is an effective nutritional prognostic tool for predicting prognosis and muscle volume loss complication in HCC patients treated with Atez/Bev. 相似文献7.
Vitamin D‐related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C
下载免费PDF全文
![点击此处可从《Journal of medical virology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
8.
Shigeru Nakai Kunitoshi Iseki Noritomo Itami Satoshi Ogata Junichiro James Kazama Naoki Kimata Takashi Shigematsu Toshio Shinoda Tetsuo Shoji Kazuyuki Suzuki Masatomo Taniguchi Kenji Tsuchida Hidetomo Nakamoto Hiroshi Nishi Seiji Hashimoto Takeshi Hasegawa Norio Hanafusa Takayuki Hamano Naohiko Fujii Ikuto Masakane Seiji Marubayashi Osamu Morita Kunihiro Yamagata Kenji Wakai Atsushi Wada Yuzo Watanabe Yoshiharu Tsubakihara 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2012,16(6):483-521
A nationwide statistical survey of 4226 dialysis facilities was conducted at the end of 2010, and 4166 facilities (98.6%) responded. The number of new patients introduced into dialysis was 37 512 in 2010. This number has decreased for two consecutive years since it peaked in 2008. The number of patients who died in 2010 was 28 882, which has been increasing every year. The number of patients undergoing dialysis at the end of 2010 was 298 252, which is an increase of 7591 (2.6%) compared with that at the end of 2009. The number of dialysis patients per million at the end of 2010 was 2329.1. The crude death rate of dialysis patients in 2010 was 9.8%, and has been gradually increasing. The mean age of the new patients introduced into dialysis was 67.8 years and the mean age of the entire dialysis patient population was 66.2 years. Regarding the primary disease of the new patients introduced into dialysis, the percentage of patients with diabetic nephropathy was 43.6%, which is a slight decrease from that in the previous year (44.5%). Patients with diabetic nephropathy as the primary disease accounted for 35.9% of the entire dialysis patient population, which approaches the percentage of patients with chronic glomerulonephritis as the primary disease (36.2%). The percentage of patients who had undergone carpal tunnel release surgery (CTx) was 4.3%, which is a slight decrease from that at the end of 1999 (5.5%). The decrease in the percentage of patients who had undergone CTx was significant among the patients with dialysis durations of 20–24 years (1999, 48.0%; 2010, 23.2%). A total weekly Kt/V attributable to peritoneal dialysis and their residual functional kidney was 1.7 or higher for 59.4% of patients who underwent peritoneal dialysis. 相似文献
9.
Shigeru Nakai Ikuto Masakane Takashi Akiba Takashi Shigematsu Kunihiro Yamagata Yuzo Watanabe Kunitoshi Iseki Noritomo Itami Toshio Shinoda Kunio Morozumi Tetsuo Shoji Seiji Marubayashi Osamu Morita Naoki Kimata Tatsuya Shoji Kazuyuki Suzuki Kenji Tsuchida Hidetomo Nakamoto Takayuki Hamano Akihiro Yamashita Kenji Wakai Atsushi Wada Yoshiharu Tsubakihara 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2008,12(6):428-456
A statistical survey of dialysis patients for the year 2006 was carried out for 4051 medical facilities across Japan, and responses were received from 3985 (98.37%) facilities. There were 264 473 dialysis patients (including 9003 peritoneal dialysis patients) in Japan at the end of 2006, which showed an increase of 6708 (2.6%) from the end of 2005. The number of patients per million population was 2069.9. The crude mortality rate during 2006 was 9.2%. The mean age of the patients who began dialysis (in 2006) was 66.4 years, and the mean age of the entire dialysis population was 64.4 years. The primary renal diseases of the patients who began dialysis were diabetic nephropathy (42.9%), chronic glomerulonephritis (25.6%), and nephrosclerosis (9.4%). Of the 3488 facilities that participated in the survey on the dialysate water quality, 2873 facilities (82.4%) measured the endotoxin concentration in the dialysate; and 1197 facilities (37.1%) out of 3228 measured the bacterial count in the dialysate. The mean hemoglobin concentration in the dialysis population at the end of 2006 was 10.23 ± 1.33 g/dL, which was equal to that at the end of 2005 (10.23 ± 1.37 g/dL). The mean concentration of serum creatinine in 15 853 patients who started dialysis during 2006 was 8.37 ± 3.58 mg/dL. The estimated glomerular filtration rate, which was calculated with formula modified for the Japanese population from the Modification of Diet in Renal Disease (MDRD) Study equation, was 5.46 ± 6.60 mL/min/1.73 m2. 相似文献
10.
Masanori Atsukawa Akihito Tsubota Noritomo Shimada Chisa Kondo Norio Itokawa Ai Nakagawa Satomi Hashimoto Takeshi Fukuda Yoko Matsushita Hideko Kidokoro Yoshiyuki Narahara Katsuhisa Nakatsuka Katsuhiko Iwakiri Chiaki Kawamoto Choitsu Sakamoto 《Hepatitis monthly》2013,13(12)